Roche’s Bispecific Antibody Columvi Gains Edge On AbbVie And Genmab’s Epkinly Following Latest Data
United States / Tue 23 Apr, 2024
Key View
- Roche’s latest Columvi data will support the drug’s full approval in the US and Europe.
- Approval as an earlier line treatment will give Roche an edge over AbbVie and Genmab’s Epkinly.
- Bispecific therapies will continue to attract interest from cancer drugmakers.
Roche’s latest Columvi (glofitamab) data will support the drug’s full